Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
Eton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results • Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule • Q3 2026 fully diluted GAAP EPS of
How this was made
The 30-second read
Why it matters
The raised guidance reflects accelerated commercial traction and may attract new capital to the stock.
Market read
Eton's earnings beat and raised guidance provide fresh material for traders, likely prompting a short‑term rally.
What to watch
Potential regulatory delays for upcoming label expansions could temper growth expectations.
Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; 2026 revenue guidance raised to more than $175 million.
Third-quarter revenue increased 158% year over year to $57.9 million, adjusted EBITDA margin reached 49%, and the Company raised both 2026 revenue and adjusted EBITDA margin guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 product sales, netGAAP | $57.92M | – | 158% |
| Q3 2026 total net revenuesGAAP | $57.92M | – | 158% |
| Q3 2026 gross profitGAAP | $44.30M | – | 464% |
| Q3 2026 adjusted gross profitnon-GAAP | $46.2M | – | – |
| Q3 2026 adjusted gross marginnon-GAAP | 80% | – | – |
| Q3 2026 research and development expensesGAAP | $5.3M | – | – |
| Q3 2026 general and administrative expensesGAAP | $16M | – | 98% |
| Q3 2026 adjusted general and administrative expensenon-GAAP | $12.8M | – | – |
| Q3 2026 total operating expensesGAAP | $21.29M | – | – |
| Q3 2026 income from operationsGAAP | $23.01M | – | – |
| Q3 2026 EBITDAnon-GAAP | $24.8M | – | – |
| Q3 2026 Adjusted EBITDAnon-GAAP | $28.5M | – | – |
| Q3 2026 Adjusted EBITDA marginnon-GAAP | 49% of revenue | – | – |
| Q3 2026 net incomeGAAP | $35.2M | – | – |
| Q3 2026 basic EPSGAAP | $1.23 | – | – |
| Q3 2026 diluted EPSGAAP | $1.06 per diluted share | – | – |
| Q3 2026 non-GAAP net incomenon-GAAP | $16.5M | – | – |
| Q3 2026 non-GAAP diluted EPSnon-GAAP | $0.50 per diluted share | – | – |
| Nine months ended September 30, 2026 product sales, netGAAP | $119.8M | – | – |
| Nine months ended September 30, 2026 licensing revenueGAAP | — | – | – |
| Nine months ended September 30, 2026 total net revenuesGAAP | $119.8M | – | – |
| Nine months ended September 30, 2026 gross profitGAAP | $84.45M | – | – |
| Nine months ended September 30, 2026 income from operationsGAAP | $38.22M | – | – |
| Nine months ended September 30, 2026 net incomeGAAP | $48.38M | – | – |
| Nine months ended September 30, 2026 diluted EPSGAAP | $1.48 | – | – |
| Nine months ended September 30, 2026 Adjusted EBITDAnon-GAAP | $50.48M | – | – |
| Nine months ended September 30, 2026 non-GAAP diluted EPSnon-GAAP | $1.08 | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full-year 2026 outlook
- Revenuemore than $175 million
- Noteat least a 40% Adjusted EBITDA margin for 2026
- Notefull-year 2026 adjusted gross margin to exceed 70%
What drove it
- Revenue growth was driven by the addition of HEMANGEOL revenue and higher product sales for INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, DESMODA and Carglumic Acid.
- Third-quarter revenue included $1.2 million of revenue from INCRELEX and GALZIN sales outside the United States.
- Gross-profit growth reflected increased product sales and a favorable change in product mix.
- The Company recorded all-time high active patient counts for INCRELEX, HEMANGEOL, ALKINDI SPRINKLE, KHINDIVI, DESMODA and GALZIN.
- The third-quarter income tax benefit reflected the release of the valuation allowance associated with federal and a portion of state deferred tax assets.
Concerns
- GAAP net income included an income tax benefit from the release of deferred tax asset valuation allowances; this benefit was removed for purposes of non-GAAP net income.
- General and administrative expense rose 98%, driven by higher stock-based compensation, compensation and benefits, operating costs supporting a larger business and expanded portfolio, and higher FDA fees.
- Research and development expense increased primarily because of the $3 million payment for ASN-001 rights and higher Glyburide Oral Suspension development spending.
- ET-700 hepatic copper uptake decreased 12%, compared with a 46% decrease with GALZIN; the Company plans additional 2027 study arms evaluating faster-release formulations.
What to watch
- KHINDIVI label-expansion PAS review, with a May 28, 2027 PDUFA date.
- LIBERVANT NDA review, with a March 29, 2027 PDUFA date, and the anticipated April 2027 launch if approved.
- ASN-001 bioavailability study progress and the anticipated 2027 NDA submission.
- ET-900 Phase 2 trial enrollment and dosing anticipated in the first quarter of 2027.
- Glyburide Oral Suspension NDA submission targeted near the end of 2026 or early 2027.
- The Company expects continued organic growth from key promoted products through the remainder of 2026 and beyond.
Balance sheet and cash flow
- Cash and cash equivalents as of September 30, 2026: $55.6 million.
- Short-term debt, net of debt discount as of September 30, 2026: $11,842 (in thousands).
- Long-term debt, net of current portion, debt discount and accrued exit fees as of September 30, 2026: $11,227 (in thousands).
- Nine months ended September 30, 2026 net cash from operating activities: $49,901 (in thousands), compared with $22,075 (in thousands).
- Nine months ended September 30, 2026 net cash used in investing activities: $(18,308) (in thousands), compared with $(284) (in thousands).
- Nine months ended September 30, 2026 purchases of product license rights: $(18,225) (in thousands).
- Nine months ended September 30, 2026 repayment of long-term debt: $(8,000) (in thousands).
- Cash and cash equivalents at September 30, 2026: $55,628 (in thousands), compared with $25,942 (in thousands) at December 31, 2025.
Analysis
Eton reported a record third quarter, with total net revenue of $57.9 million versus $22.5 million in the prior-year period, a reported 158% increase. Product sales were the sole source of third-quarter revenue, while the nine-month comparison also reflects the absence of prior-year licensing revenue. Management attributed the quarterly increase to HEMANGEOL and growth across INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, DESMODA and Carglumic Acid. The Company also cited all-time high active patient counts across its key promoted products.
Profitability expanded materially. GAAP gross profit was $44.3 million compared with $7.9 million, while adjusted gross margin was 80% compared with 45%. Adjusted EBITDA was $28.5 million, or 49% of revenue, compared with $2.9 million, or 13% of revenue, in the prior-year quarter and 43% in the second quarter of 2026. Management attributed the gross-profit improvement to greater product sales and favorable product mix.
GAAP net income was $35.2 million, or $1.06 per diluted share, compared with a net loss of $1.9 million, or $0.07 per diluted share. The result included a tax benefit from releasing valuation allowances on federal and certain state deferred tax assets. Non-GAAP net income, which excluded that one-time benefit, was $16.5 million, or $0.50 per diluted share, compared with $1.5 million, or $0.04 per diluted share. Higher operating costs accompanied the commercial expansion: R&D reflected the $3 million ASN-001 rights payment and Glyburide spending, while G&A rose 98% amid compensation, headcount, portfolio-support costs and FDA fees.
The balance sheet and cash generation strengthened through the first nine months. Cash and cash equivalents reached $55.6 million at September 30, 2026, and net cash from operating activities was $49.9 million for the nine-month period. Investing cash use included $18.2 million of product license rights purchases, while financing activity included an $8.0 million long-term debt repayment.
Management raised full-year 2026 revenue guidance to more than $175 million from more than $145 million and increased its Adjusted EBITDA margin outlook to at least 40% from at least 35%. The forward commercial and development agenda includes anticipated 2027 milestones for KHINDIVI, LIBERVANT, ASN-001, ET-900 and Glyburide Oral Suspension. The report also identifies product and regulatory execution as central to sustaining the current growth and margin trajectory.
Management, verbatim
Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule. The team also demonstrated exceptional operational execution, significantly expanding margins, and delivering an adjusted EBITDA margin of 49%. We are raising both our revenue and adjusted EBITDA guidance for 2026, reflecting the strong momentum in our business.
Sean Brynjelsen, CEO of Eton Pharmaceuticals
Growth remained strong across the portfolio, with record levels of active patients for all of our key products, including HEMANGEOL ® , INCRELEX ® , ALKINDI SPRINKLE ® , KHINDIVI ® , GALZIN ® and DESMODA TM . Our recent licensing agreement for LIBERVANT ® adds another potential major 2027 launch and will expand us into neurology, giving us an additional therapeutic platform to build on with future transactions.
Sean Brynjelsen, CEO of Eton Pharmaceuticals
Not in the filing
stated, not guessed- Previous-release outlook was not provided; therefore, actual results were not compared with prior guidance.
- Revenue by reportable operating segment or individual product was not reported.
- GAAP gross margin was not reported.
- Quarterly operating cash flow was not reported.
- Free cash flow was not reported.
- Share repurchases and dividends were not reported.
- Capital-return activity was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Eton Pharmaceuticals disclosed Q3 2026 results, highlighting record product sales, margin expansion, and new licensing agreements.
Ticker impact
Eton Pharmaceuticals raised 2026 revenue guidance to >$175M and Adjusted EBITDA guidance to >40% in its Q3 2026 earnings release.
likely upside as market prices in raised guidance
The company reported 158% YoY revenue growth and increased margins, then lifted guidance, which typically drives buying pressure.
Market effects
Boosts sentiment for rare‑disease biotech sector as a peer shows strong top‑line growth.
Positive for US biotech equities.
Limited to investors tracking niche pharma pipelines.
Counterpoint
If the guidance raise is already priced in, the stock may face short‑term profit‑taking.
Key entities
- companyEton Pharmaceuticals
Nasdaq‑listed biotech focused on rare diseases.
